Verona Pharma PLC ADR (VRNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Verona Pharma PLC ADR (VRNA) has a cash flow conversion efficiency ratio of 0.110x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.56 Million) by net assets ($278.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VRNA equity to assets ratio to measure how much of total assets are equity-financed.
Verona Pharma PLC ADR - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Verona Pharma PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Verona Pharma PLC ADR (VRNA) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Verona Pharma PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verona Pharma PLC ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Andritz AG
VI:ANDR
|
0.044x |
|
NIBE Industrier AB (publ)
ST:NIBE-B
|
0.100x |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
0.087x |
|
The Phoenix Mills Limited
NSE:PHOENIXLTD
|
0.086x |
|
BARRY CALLEBA. ADR 1/100
F:BCLM
|
N/A |
|
Applied Digital Corporation
NASDAQ:APLD
|
0.038x |
|
Nantong Jianghai Capacitor Co Ltd
SHE:002484
|
0.075x |
|
National Fuel Gas Company
NYSE:NFG
|
0.100x |
Annual Cash Flow Conversion Efficiency for Verona Pharma PLC ADR (2005–2024)
The table below shows the annual cash flow conversion efficiency of Verona Pharma PLC ADR from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see VRNA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $204.56 Million | $-122.20 Million | -0.597x | -196.53% |
| 2023-12-31 | $249.28 Million | $-50.22 Million | -0.201x | +22.44% |
| 2022-12-31 | $230.47 Million | $-59.86 Million | -0.260x | -15.61% |
| 2021-12-31 | $148.00 Million | $-33.25 Million | -0.225x | +7.86% |
| 2020-12-31 | $184.85 Million | $-45.08 Million | -0.244x | +75.58% |
| 2019-12-31 | $44.40 Million | $-44.34 Million | -0.999x | -247.03% |
| 2018-12-31 | $79.86 Million | $-22.98 Million | -0.288x | -11.07% |
| 2017-12-31 | $107.95 Million | $-27.97 Million | -0.259x | -59.81% |
| 2016-12-31 | $42.53 Million | $-6.89 Million | -0.162x | +85.74% |
| 2015-12-31 | $8.28 Million | $-9.41 Million | -1.137x | -304.82% |
| 2014-12-31 | $19.62 Million | $-5.51 Million | -0.281x | +71.73% |
| 2013-12-31 | $3.41 Million | $-3.39 Million | -0.993x | -2.41% |
| 2012-12-31 | $4.21 Million | $-4.08 Million | -0.970x | -149.67% |
| 2011-12-31 | $6.29 Million | $-2.44 Million | -0.389x | +19.22% |
| 2010-12-31 | $5.33 Million | $-2.56 Million | -0.481x | -33.08% |
| 2009-12-31 | $7.25 Million | $-2.62 Million | -0.361x | -6.93% |
| 2008-12-31 | $5.85 Million | $-1.98 Million | -0.338x | +18.99% |
| 2007-12-31 | $5.73 Million | $-2.39 Million | -0.417x | -363.37% |
| 2006-12-31 | $7.64 Million | $-687.68K | -0.090x | -4507.76% |
| 2005-12-31 | $1.68 Million | $3.44K | 0.002x | -- |
About Verona Pharma PLC ADR
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more